Valerio Therapeutics (C4X) Ratios
Valerio Therapeutics Ratios
DE:C4X's free cash flow for Q2 2026 was $-1.19M. For the 2026 fiscal year, DE:C4X's free cash flow was decreased by $-503.00K and operating cash flow was $-683.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Jun 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.76 | 0.25 | 1.17 | 2.88 | 4.27 |
| Quick Ratio | 0.76 | 0.25 | 1.17 | 2.77 | 4.06 |
| Cash Ratio | 0.17 | 0.06 | 0.61 | 2.04 | 2.53 |
| Solvency Ratio | 0.00 | -0.48 | -0.91 | -0.94 | -0.27 |
| Operating Cash Flow Ratio | 0.29 | -0.68 | -1.67 | -1.32 | -1.21 |
| Short-Term Operating Cash Flow Coverage | 2.01 | -1.71 | -12.85 | -9.41 | -2.90 |
| Net Current Asset Value | $ -8.38M | $ -21.63M | $ -7.47M | $ -237.00K | $ 10.01M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.50 | 0.75 | 0.26 | 0.23 | 0.19 |
| Debt-to-Equity Ratio | 3.67 | -1.50 | 0.61 | 0.45 | 0.30 |
| Debt-to-Capital Ratio | 0.79 | 2.98 | 0.38 | 0.31 | 0.23 |
| Long-Term Debt-to-Capital Ratio | 0.75 | -1.71 | 0.32 | 0.27 | 0.13 |
| Financial Leverage Ratio | 7.34 | -2.01 | 2.38 | 1.93 | 1.61 |
| Debt Service Coverage Ratio | 0.23 | -1.63 | -12.20 | -5.41 | -1.43 |
| Interest Coverage Ratio | -1.96 | -52.68 | -307.39 | -7.79 | -6.04 |
| Debt to Market Cap | 0.34 | 1.12 | 0.37 | 0.32 | 0.34 |
| Interest Debt Per Share | 0.05 | 0.09 | 0.07 | 0.12 | 0.13 |
| Net Debt to EBITDA | 12.09 | -1.02 | -0.12 | 0.26 | 1.36 |
| Profitability Margins | |||||
| Gross Profit Margin | 67.08% | 71.39% | 70.39% | 64.38% | 90.94% |
| EBIT Margin | -169.30% | -1303.74% | -1121.50% | -1185.93% | -156.77% |
| EBITDA Margin | 21.06% | -672.73% | -1024.67% | -1180.67% | -144.19% |
| Operating Profit Margin | -21.38% | -919.63% | -1127.11% | -1186.07% | -180.38% |
| Pretax Profit Margin | -180.22% | -1313.61% | -1129.28% | -1335.62% | -186.66% |
| Net Profit Margin | -190.36% | -1334.69% | -1130.22% | -1355.65% | -146.16% |
| Continuous Operations Profit Margin | -190.36% | -1334.63% | -1130.11% | -1355.37% | -146.13% |
| Net Income Per EBT | 105.63% | 101.60% | 100.08% | 101.50% | 78.30% |
| EBT Per EBIT | 843.09% | 142.84% | 100.19% | 112.61% | 103.48% |
| Return on Assets (ROA) | -32.15% | -133.48% | -57.67% | -45.40% | -11.19% |
| Return on Equity (ROE) | -236.05% | 267.98% | -137.41% | -87.84% | -18.02% |
| Return on Capital Employed (ROCE) | -6.16% | 4041.42% | -84.03% | -47.63% | -15.93% |
| Return on Invested Capital (ROIC) | -5.50% | -228.54% | -78.26% | -45.67% | -14.82% |
| Return on Tangible Assets | -69.35% | -401.46% | -137.99% | -87.51% | -18.25% |
| Earnings Yield | -22.99% | -207.36% | -90.91% | -68.51% | -24.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.32 | 1.04 | 0.95 | 0.98 | 0.48 |
| Payables Turnover | 0.37 | 0.10 | 0.22 | 0.15 | 0.13 |
| Inventory Turnover | 0.00 | 0.00 | 88.83 | 0.69 | 0.25 |
| Fixed Asset Turnover | 2.03 | 1.53 | 1.18 | 0.76 | 1.82 |
| Asset Turnover | 0.17 | 0.10 | 0.05 | 0.03 | 0.08 |
| Working Capital Turnover Ratio | -0.34 | -0.30 | 0.24 | 0.08 | 0.20 |
| Cash Conversion Cycle | -707.34 | -3380.66 | -1294.87 | -1546.76 | -602.36 |
| Days of Sales Outstanding | 276.48 | 352.58 | 384.26 | 374.11 | 767.38 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 4.11 | 528.33 | 1439.17 |
| Days of Payables Outstanding | 983.82 | 3733.25 | 1683.25 | 2449.19 | 2808.91 |
| Operating Cycle | 276.48 | 352.58 | 388.37 | 902.43 | 2206.55 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.01 | -0.08 | -0.14 | -0.09 | -0.10 |
| Free Cash Flow Per Share | 0.00 | -0.08 | -0.14 | -0.09 | -0.10 |
| Dividend Paid and CapEx Coverage Ratio | 1.40 | -39.06 | -101.62 | -19.35 | -61.67 |
| Capital Expenditure Coverage Ratio | 1.40 | -39.06 | -101.62 | -19.35 | -61.67 |
| Operating Cash Flow Coverage Ratio | 0.24 | -0.93 | -2.07 | -0.94 | -0.86 |
| Operating Cash Flow to Sales Ratio | 0.71 | -6.95 | -10.33 | -6.54 | -2.11 |
| Free Cash Flow Yield | 2.45% | -110.73% | -83.92% | -34.78% | -36.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.35 | -0.48 | -1.10 | -1.46 | -4.01 |
| Price-to-Sales (P/S) Ratio | 8.28 | 6.44 | 12.43 | 19.79 | 5.86 |
| Price-to-Book (P/B) Ratio | 10.27 | -1.29 | 1.51 | 1.28 | 0.72 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 40.89 | -0.90 | -1.19 | -2.87 | -2.73 |
| Price-to-Operating Cash Flow Ratio | 11.58 | -0.93 | -1.20 | -3.02 | -2.78 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | -0.07 | 0.07 | -0.01 | 0.01 |
| Enterprise Value Multiple | 51.40 | -1.97 | -1.33 | -1.41 | -2.71 |
| Enterprise Value | 27.86M | 23.80M | 24.56M | 24.05M | 15.86M |
| EV to EBITDA | 51.40 | -1.97 | -1.33 | -1.41 | -2.71 |
| EV to Sales | 10.83 | 13.27 | 13.64 | 16.67 | 3.91 |
| EV to Free Cash Flow | 53.47 | -1.86 | -1.31 | -2.42 | -1.82 |
| EV to Operating Cash Flow | 15.15 | -1.91 | -1.32 | -2.55 | -1.85 |
| Tangible Book Value Per Share | -0.04 | -0.13 | -0.04 | 0.01 | 0.14 |
| Shareholders’ Equity Per Share | 0.01 | -0.06 | 0.11 | 0.21 | 0.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.06 | -0.02 | -0.00 | -0.01 | -0.01 |
| Revenue Per Share | 0.02 | 0.01 | 0.01 | 0.01 | 0.05 |
| Net Income Per Share | -0.03 | -0.16 | -0.15 | -0.18 | -0.07 |
| Tax Burden | 1.06 | 1.02 | 1.00 | 1.01 | 0.78 |
| Interest Burden | 1.06 | 1.01 | 1.01 | 1.13 | 1.19 |
| Research & Development to Revenue | 0.22 | 2.87 | 5.38 | 7.66 | 1.21 |
| SG&A to Revenue | 0.82 | 1.48 | 1.45 | 1.83 | 0.58 |
| Stock-Based Compensation to Revenue | 0.03 | 0.22 | 0.29 | 0.50 | 0.06 |
| Income Quality | -0.38 | 0.52 | 0.91 | 0.48 | 1.44 |
Currency in EUR
